| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6636b59c3149a23a6ae7feaa3984d05f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5152
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2840-203
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-575 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4702
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0693
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70575 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-16 |
| filingDate |
2019-07-22^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d3dfc03ce090b68fd98089f4297f562
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_400faa583116cb61b56d47a623a4d439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c49890aaf91f9ca9f886a43f98db83d5 |
| publicationDate |
2020-01-30^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020023350-A1 |
| titleOfInvention |
Major histocompatibility complex class ll-expressing cancer cell vaccine and methods of use for producing integrated immune responses |
| abstract |
Provided are modified cancer cells that are modified to co-express class II trans-activator (CIITA), and an immuno-stimulatory molecule. The immuno-stimulatory molecule is OX-40-ligand or 4-lBB-Ligand. Methods of making the cells are provided by introducing polynucleotides encoding the CIITA and the immune-stimulatory molecule into cancer cells. Methods of stimulating humoral and cell-mediated immune responses by administering the modified cancer cells, or polynucleotides encoding the CIITA and immune-stimulatory molecules are also provided. These approaches can be used to stimulate an immune response against any of a wide variety of cancer antigens. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11674121-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023008814-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11248213-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2794757-C1 |
| priorityDate |
2018-07-22^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |